Peptides for Anxiety: Selank, Semax and the Russian Trial Literature

Selank and semax occupy an unusual position. Unlike most research peptides they have been through clinical trials in humans, are registered medicines in Russia, and have published efficacy data — almost all of it in Russian-language journals.

That combination makes them harder to assess than compounds with no evidence at all, because the evidence exists and is difficult for most readers to appraise.

Selank

Selank is a synthetic analogue of tuftsin, a naturally occurring immunomodulatory peptide, with a sequence modification intended to extend its stability.

The published clinical work includes:

• A 2008 study examining efficacy and possible mechanisms in generalised anxiety disorder and neurasthenia.

• A 2014 comparison against phenazepam, a benzodiazepine, assessing both anxiolytic effect and tolerability.

• A 2015 study on optimising treatment of anxiety disorders with selank.

How to weigh the Russian literature

Dismissing this evidence outright is not justified, and accepting it uncritically is not either. The specific limitations are worth naming:

The honest summary: this is real clinical research that has not been independently replicated or reviewed by a Western regulator. It sits above "rodent studies only" and below "approved drug", and there is no shorthand for that position.

Semax

Semax is an analogue of ACTH(4-10), modified so that it lacks the hormonal activity of the parent fragment. A 2006 Brain Research paper found that semax regulates BDNF and trkB expression in the rat hippocampus — a plausible and specific mechanism, since BDNF signalling is implicated in both mood and cognition.

Semax is more often positioned for cognition than for anxiety, and the two compounds are frequently confused. See semax vs selank for the distinction.

The nasal route

Both are commonly supplied as nasal sprays rather than for injection, which is unusual in this market and is a deliberate design feature rather than a convenience.

• Intranasal administration is proposed to allow some access to the central nervous system.

• Both are small peptides, which is relevant to whether that route is plausible at all.

• Bioavailability by this route is not well characterised for either compound in the accessible literature.

• Concentration and delivered volume vary between preparations, so "sprays" is not a dose. The peptide calculator does not help here, because the delivered volume per actuation is a property of the device.

Status

What anxiety treatment has stronger evidence for

Anxiety disorders are among the best-studied conditions in medicine, and the interventions with large, replicated, independently reviewed trial evidence are:

1. Cognitive behavioural therapy — comparable to medication in effect size for many anxiety disorders, without pharmacological risk.

2. SSRIs and SNRIs — first-line pharmacotherapy with extensive evidence.

3. Buspirone for generalised anxiety.

4. Exercise — consistent, moderate effects across trials.

5. Sleep and alcohol assessment, since both are common and modifiable contributors.

See the selank dosage guide and the semax benefits guide.